Relacorilant is an investigational drug that functions as a selective glucocorticoid receptor modulator (SGRM). It is designed to regulate the activity of cortisol by selectively blocking glucocorticoid receptors, without affecting other hormone pathways such as progesterone. This selective mechanism differentiates relacorilant from earlier therapies and may help reduce side effects associated with non-selective treatments.
The drug is primarily being studied for the treatment of endogenous Cushing’s syndrome, a condition characterized by excessive cortisol levels in the body. Elevated cortisol can lead to serious health issues such as diabetes, hypertension, weight gain, and cardiovascular complications. By modulating cortisol activity, relacorilant aims to control these symptoms and improve overall metabolic health.
In addition to Cushing’s syndrome, relacorilant is also under clinical investigation for use in oncology. It is being evaluated in combination with chemotherapy agents, particularly in cancers such as ovarian cancer, where cortisol signaling may contribute to tumor resistance and progression. By blocking glucocorticoid receptors, relacorilant may enhance the effectiveness of anticancer therapies.
Clinical studies have shown promising results in improving glucose metabolism and reducing the clinical symptoms associated with hypercortisolism. Unlike some other glucocorticoid receptor antagonists, relacorilant does not significantly interfere with progesterone receptors, which may lower the risk of hormonal side effects.
As an investigational therapy, relacorilant is not yet widely approved for routine clinical use and is typically available through clinical trials. Ongoing research is focused on confirming its safety, long-term efficacy, and potential role in both endocrine disorders and cancer treatment.
Common side effects observed in studies may include fatigue, nausea, headache, and peripheral edema, although the full safety profile continues to be evaluated.
Overall, relacorilant represents an important advancement in targeted hormone modulation therapy, offering a more selective and potentially better-tolerated approach for managing cortisol-related disorders and improving outcomes in certain cancers.
Overview
Relacorilant is an investigational drug that functions as a selective glucocorticoid receptor modulator (SGRM). It is designed to regulate the activity of cortisol by selectively blocking glucocorticoid receptors, without affecting other hormone pathways such as progesterone. This selective mechanism differentiates relacorilant from earlier therapies and may help reduce side effects associated with non-selective treatments.
The drug is primarily being studied for the treatment of endogenous Cushing’s syndrome, a condition characterized by excessive cortisol levels in the body. Elevated cortisol can lead to serious health issues such as diabetes, hypertension, weight gain, and cardiovascular complications. By modulating cortisol activity, relacorilant aims to control these symptoms and improve overall metabolic health.
In addition to Cushing’s syndrome, relacorilant is also under clinical investigation for use in oncology. It is being evaluated in combination with chemotherapy agents, particularly in cancers such as ovarian cancer, where cortisol signaling may contribute to tumor resistance and progression. By blocking glucocorticoid receptors, relacorilant may enhance the effectiveness of anticancer therapies.
Clinical studies have shown promising results in improving glucose metabolism and reducing the clinical symptoms associated with hypercortisolism. Unlike some other glucocorticoid receptor antagonists, relacorilant does not significantly interfere with progesterone receptors, which may lower the risk of hormonal side effects.
As an investigational therapy, relacorilant is not yet widely approved for routine clinical use and is typically available through clinical trials. Ongoing research is focused on confirming its safety, long-term efficacy, and potential role in both endocrine disorders and cancer treatment.
Common side effects observed in studies may include fatigue, nausea, headache, and peripheral edema, although the full safety profile continues to be evaluated.
Overall, relacorilant represents an important advancement in targeted hormone modulation therapy, offering a more selective and potentially better-tolerated approach for managing cortisol-related disorders and improving outcomes in certain cancers.